Oncopeptides

Oncopeptides FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Oncopeptides (ONCO.ST) as of Nov 10, 2026 is 89.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.68 % — a change of -2.59% (lower).

FCF Conversion

89.30 %

YoY

-2.59%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Oncopeptides is 2025 89.30 % . FCF Conversion Rate (FCF/EBITDA) of Oncopeptides was 2024 91.68 % . It decreases by -2.59% lower compared to the previous year.

The Oncopeptides FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
79.65 SEK
Jan 1, 2019
93.59 SEK
Jan 1, 2020
82.38 SEK
Jan 1, 2021
106.04 SEK
Jan 1, 2022
125.17 SEK
Jan 1, 2023
112.24 SEK
Jan 1, 2024
91.68 SEK
Jan 1, 2025
89.30 SEK
The Oncopeptides FCF Conversion history
YEARFCF ConversionYoY
89.30 %-2.59%
91.68 %-18.32%
112.24 %-10.33%
125.17 %+18.04%
106.04 %+28.72%
82.38 %-11.98%
93.59 %+17.49%
79.65 %-27.75%
110.24 %+19.72%
92.08 %-8.92%
101.09 %+2.77%
98.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncopeptides Stock analysis

What does Oncopeptides do? Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncopeptides stock

FCF Conversion Rate (FCF/EBITDA) of Oncopeptides is 89.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Oncopeptides changed from 91.68 % to 89.30 %, representing a -2.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Oncopeptides since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Oncopeptides with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Oncopeptides

All Key Metrics — Oncopeptides